Amicus Therapeutics, Inc. (FOLD)
| Market Cap | 4.55B |
| Revenue (ttm) | 634.21M |
| Net Income (ttm) | -27.11M |
| Shares Out | 314.00M |
| EPS (ttm) | -0.09 |
| PE Ratio | n/a |
| Forward PE | 39.70 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 14.49 |
| Day's Range | n/a |
| 52-Week Range | 5.51 - 14.50 |
| Beta | 0.48 |
| Analysts | Buy |
| Price Target | 27.25 (+88.06%) |
| Earnings Date | May 6, 2026 |
About FOLD
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecu... [Read more]
Financial Performance
In 2025, Amicus Therapeutics's revenue was $634.21 million, an increase of 20.05% compared to the previous year's $528.30 million. Losses were -$27.11 million, -51.68% less than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for FOLD stock is "Buy." The 12-month stock price target is $27.25, which is an increase of 88.06% from the latest price.
News
Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications
NEW YORK--(BUSINESS WIRE)--LSTA, the trade association for the U.S. corporate lending market, today was joined by SIFMA, the MFA, the Investment Company Institute and the Creditor Rights Coalition, in...
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions P...
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold® (migalastat) in Fa...
Top 3 Health Care Stocks That May Implode In Q1
As of Feb. 2, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Amicu...
BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.
It's the second acquisition for BioMarin in 2025, as the company seeks to diversify its product portfolio after the commercial failure of a hemophilia A gene therapy.
BioMarin to Buy Amicus Therapeutics for $4.8 Billion
BioMarin Pharmaceutical has struck a deal to buy fellow biotechnology company Amicus Therapeutics for about $4.8 billion in cash.
BioMarin to acquire Amicus Therapeutics for $4.8 Billion
BioMarin Pharmaceutical said on Friday it will acquire Amicus Therapeutics in an all-cash deal worth about $4.8 billion.
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Milli...
Amicus Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Strong revenue growth and profitability were highlighted, with Galafold and Pombiliti/Opfolda driving expansion in rare disease markets. The pipeline advanced with the DMX-200 FSGS program, and financial discipline remains a priority as the company eyes further late-stage asset deals.
Amicus Therapeutics Transcript: UBS Global Healthcare Conference 2025
Strong financial performance and product growth are driven by increased diagnosis, global expansion, and robust real-world data. Key catalysts include IP litigation outcomes, label expansions, and DMX-200 trial progress, with a focus on rare disease markets and stable pricing.
Amicus Therapeutics Earnings Call Transcript: Q3 2025
Q3 2025 saw 19% revenue growth, GAAP profitability, and record demand for Galafold and Pombiliti/Opfolda. Guidance for 2025 was reiterated, with strong growth expected in both core products and continued pipeline progress, including DMX-200 for FSGS.
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
Q3 2025 Total Revenue of $169M, up 17% at CER Positive Q3 2025 GAAP Net Income of $17M Cash Position of $264M, a $33M Increase in Q3 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N...
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025
PRINCETON, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i...
Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025
PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025, ...
Amicus Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Strong Q2 sales and robust growth in rare disease therapies are driving a path to GAAP profitability by late 2025. Expansion of Galafold and Pombiliti/Opfolda continues globally, while pipeline and BD efforts focus on late-stage, high-potential assets.
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM
Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda® Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Cl...
Amicus Therapeutics Transcript: Cantor Global Healthcare Conference 2025
Strong commercial growth continues for both Fabry and Pompe therapies, with Galafold maintaining high market share and compliance. Pipeline expansion includes DMX-200 for FSGS, supported by positive interim data and regulatory alignment. Profitability and further pipeline additions are expected in the near term.
In NCLA Amicus Win, en Banc Federal Circuit Rules Trump's Emergency Tariffs Are Unlawful
V.O.S. Selections, Inc.; Plastic Services and Products, LCC, d/b/a Genova Pipe; MicroKits, LCC; FishUSA Inc.; Terry Precision Cycling LLC v. President Donald J. Trump, et al. V.O.S. Selections, Inc.; ...
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025
PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences i...
Multiple Jewish Organizations File Second Circuit Amicus Brief in Support of Previously Detained Tufts Student
SEATTLE--(BUSINESS WIRE)--A coalition of American Jewish organizations have filed an amicus brief in the United States Court of Appeals for the Second Circuit in support of a Vermont federal court's c...
In NCLA Amicus Win, NY State Supreme Court, Appellate Div., Scraps Illegal Fine Against Trump
People of the State of New York, by Attorney General Letitia James v. Donald J. Trump, et al. People of the State of New York, by Attorney General Letitia James v. Donald J. Trump, et al.
The Association of American Physicians and Surgeons Filed an Amicus Brief in the Ninth Circuit in Support of Restoring California's Religious Exemption to Vaccination
Physicians file amicus brief opposing removal of religious exemptions to vaccines. Objections include components derived from pork or aborted fetal tissue.
Amicus Therapeutics Earnings Call Transcript: Q2 2025
Q2 2025 saw 22% revenue growth, driven by Galafold and Pombiliti/Opfolda, with strong global expansion and robust patient demand. Guidance for 2025 is reiterated, with positive GAAP net income expected in the second half and continued investment in late-stage assets like DMX-200.
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
Q2 2025 Total Revenue of $154.7M, up 18% at CER Galafold ® Q2 Revenue of $128.9M, up 12% at CER Pombiliti ® + Opfolda ® Q2 Revenue of $25.8M, up 58% at CER Reiterating 2025 Financial Guidance includin...